T1	outcome-Measure 720 751	pCR rate at the time of surgery
T2	total-participants 753 776	Five hundred thirty-six
T3	control-participants 811 814	266
T4	intervention-participants 826 829	270
T5	intervention 0 53	Epirubicin and docetaxel with or without capecitabine
T6	intervention-participants 886 888	44
T7	control-participants 900 902	49
T8	outcome 905 913	pCR rate
T9	iv-bin-percent 952 957	23.0%
T10	cv-bin-percent 965 970	15.4%
T11	iv-bin-percent 1042 1047	38.6%
T12	cv-bin-percent 1059 1064	26.5%
T15	iv-bin-abs 1454 1456	35
T16	cv-bin-abs 1464 1466	18
T17	eligibility 406 455	Patients with invasive breast cancer (except T4d)
T18	control 805 807	ED
T19	control 893 896	not
T13	outcome 1079 1113	Rates of axillary node involvement
T20	outcome 1129 1148	breast conservation
T14	outcome 1420 1452	number of serious adverse events
